MBD2 Ablation Impairs Lymphopoiesis and Impedes Progression and Maintenance of T-ALL.

Aberrant DNA methylation patterns in leukemia might be exploited for therapeutic targeting. In this study, we employed a genetically deficient mouse model to explore the role of the methylated DNA binding protein MBD2 in normal and malignant hematopoiesis. MBD2 ablation led to diminished lymphocytes. Functional defects of the lymphoid compartment were also observed after in vivo reconstitution of MBD2-deficient hematopoietic stem cells (HSC). In an established model of Notch1-driven T-cell acute lymphoblastic leukemia (T-ALL), MBD2 ablation impeded malignant progression and maintenance by attenuating the Wnt signaling pathway. In clinical specimens of human T-ALL, Wnt signaling pathway signatures were significantly enhanced and positively correlated with the expression and function of MBD2. Furthermore, a number of typical Wnt signaling inhibitory genes were abnormally hypermethylated in primary human T-ALL. Abnormal activation of Wnt signaling in T-ALL was switched off by MBD2 deletion, partially by reactivating epigenetically silenced Wnt signaling inhibitors. Taken together, our results define essential roles for MBD2 in lymphopoiesis and T-ALL and suggest MBD2 as a candidate therapeutic target in T-ALL.Significance: This study highlights a methylated DNA binding protein as a candidate therapeutic target to improve the treatment of T-cell acute lymphoblastic leukemias, as a new starting point for developing epigenetic therapy in this and other lymphoid malignancies. Cancer Res; 78(7); 1632-42. ©2018 AACR.

[1]  M. Boutros,et al.  Wnt signaling in cancer , 2016, Oncogene.

[2]  Ole Winther,et al.  BloodSpot: a database of gene expression profiles and transcriptional programs for healthy and malignant haematopoiesis , 2015, Nucleic Acids Res..

[3]  R. Greil,et al.  International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. , 2015, Blood.

[4]  S. Clark,et al.  Methyl-CpG-binding domain proteins: readers of the epigenome. , 2015, Epigenomics.

[5]  L. Godley,et al.  The mechanistic role of DNA methylation in myeloid leukemogenesis , 2014, Leukemia.

[6]  S. Baylin,et al.  The NuRD complex cooperates with DNMTs to maintain silencing of key colorectal tumor suppressor genes , 2014, Oncogene.

[7]  David A. Scott,et al.  Genome engineering using the CRISPR-Cas9 system , 2013, Nature Protocols.

[8]  D. Nosi,et al.  Hypermethylation of Wnt antagonist gene promoters and activation of Wnt pathway in myelodysplastic marrow cells. , 2012, Leukemia research.

[9]  D. Hwang,et al.  Notch1 counteracts WNT/β-catenin signaling through chromatin modification in colorectal cancer. , 2012, The Journal of clinical investigation.

[10]  J. Herman,et al.  Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. , 2011, Cancer discovery.

[11]  J. Berg,et al.  Dnmt3a is essential for hematopoietic stem cell differentiation , 2011, Nature Genetics.

[12]  H. Bear,et al.  Methyl-Binding Domain Protein 2–Dependent Proliferation and Survival of Breast Cancer Cells , 2011, Molecular Cancer Research.

[13]  J. Downing,et al.  Integrated Genetic and Epigenetic Analysis of Childhood Acute Lymphoblastic Leukemia Reveals a Synergistic Role for Structural and Epigenetic Lesions In Determining Disease Phenotype , 2010 .

[14]  Meijuan Huang,et al.  Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion , 2010, The Journal of experimental medicine.

[15]  C. Bonifer,et al.  Epigenetic mechanisms regulating normal and malignant haematopoiesis: new therapeutic targets for clinical medicine , 2010, Expert Reviews in Molecular Medicine.

[16]  R. Jaenisch,et al.  DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction , 2009, Nature Genetics.

[17]  G. Zheng,et al.  Kinetics of normal hematopoietic stem and progenitor cells in a Notch1-induced leukemia model. , 2009, Blood.

[18]  S. Orkin,et al.  DNA methyltransferase 1 is essential for and uniquely regulates hematopoietic stem and progenitor cells. , 2009, Cell stem cell.

[19]  K. Basler,et al.  β-Catenin hits chromatin: regulation of Wnt target gene activation , 2009, Nature Reviews Molecular Cell Biology.

[20]  A. Bird,et al.  MBD2-Mediated Transcriptional Repression of the p14ARF Tumor Suppressor Gene in Human Colon Cancer Cells , 2008, Pathobiology.

[21]  F. Prósper,et al.  Methylation status of Wnt signaling pathway genes affects the clinical outcome of Philadelphia‐positive acute lymphoblastic leukemia , 2008, Cancer science.

[22]  T. Dale,et al.  Deficiency of Mbd2 Attenuates Wnt Signaling , 2008, Molecular and Cellular Biology.

[23]  P. Jin,et al.  The loss of methyl-CpG binding protein 1 leads to autism-like behavioral deficits. , 2008, Human molecular genetics.

[24]  M. Fraga,et al.  Unmasking of epigenetically silenced candidate tumor suppressor genes by removal of methyl-CpG-binding domain proteins , 2008, Oncogene.

[25]  Guillermo Garcia-Manero,et al.  Evolution of decitabine development , 2008, Cancer.

[26]  J. Licht,et al.  Epigenetic regulation of normal and malignant hematopoiesis , 2007, Oncogene.

[27]  J. Herman,et al.  Identification of epigenetically silenced genes in tumor endothelial cells. , 2007, Cancer research.

[28]  O. Sansom,et al.  Mechanisms of Disease: methyl-binding domain proteins as potential therapeutic targets in cancer , 2007, Nature Clinical Practice Oncology.

[29]  M. Esteller.  Epigenetic gene silencing in cancer: the DNA hypermethylome. , 2007, Human molecular genetics.

[30]  S. Hoppler,et al.  Wnt signalling: variety at the core , 2007, Journal of Cell Science.

[31]  P. Wade,et al.  MBD family proteins: reading the epigenetic code , 2006, Journal of Cell Science.

[32]  F. Weerkamp,et al.  Notch and Wnt signaling in T-lymphocyte development and acute lymphoblastic leukemia , 2006, Leukemia.

[33]  W. W. Chan,et al.  Preferential methylation of Wnt inhibitory factor-1 in acute promyelocytic leukemia: an independent poor prognostic factor , 2006, Leukemia.

[34]  John M Bennett,et al.  Decitabine improves patient outcomes in myelodysplastic syndromes , 2006, Cancer.

[35]  J. Byrd,et al.  CpG island methylation and expression of the secreted frizzled-related protein gene family in chronic lymphocytic leukemia. , 2006, Cancer research.

[36]  A. Bird,et al.  Role of MBD2 in gene regulation and tumorigenesis. , 2005, Biochemical Society transactions.

[37]  Wei Dong Chen,et al.  Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer , 2004, Nature Genetics.

[38]  Eric C. Griffith,et al.  Derepression of BDNF Transcription Involves Calcium-Dependent Phosphorylation of MeCP2 , 2003, Science.

[39]  A. Bird,et al.  MBD4 deficiency reduces the apoptotic response to DNA-damaging agents in the murine small intestine , 2003, Oncogene.

[40]  A. Bird,et al.  Deficiency of Mbd2 suppresses intestinal tumorigenesis , 2003, Nature Genetics.

[41]  A. Bird,et al.  Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals , 2003, Nature Genetics.

[42]  K. Hayashi,et al.  Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. , 2002, Cancer research.

[43]  J. Holland,et al.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  J. Herman,et al.  A gene hypermethylation profile of human cancer. , 2001, Cancer research.

[45]  A. Bird,et al.  Closely related proteins MBD2 and MBD3 play distinctive but interacting roles in mouse development. , 2001, Genes & development.

[46]  D. Haber,et al.  DNA Methyltransferases Dnmt3a and Dnmt3b Are Essential for De Novo Methylation and Mammalian Development , 1999, Cell.

[47]  H Clevers,et al.  Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. , 1999, The American journal of pathology.

[48]  A. Sparks,et al.  Identification of c-MYC as a target of the APC pathway. , 1998, Science.

[49]  K. Kinzler,et al.  Constitutive Transcriptional Activation by a β-Catenin-Tcf Complex in APC−/− Colon Carcinoma , 1997, Science.

[50]  Q. Tao,et al.  Epigenetic disruption of the WNT/beta-catenin signaling pathway in human cancers. , 2009, Epigenetics.